secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0000875320-24-000193
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex Q2 product revenue $2.65B (+6% YoY); raises FY 2024 guidance to $10.65-10.85B
--------------------------------------------------------------------------------

- GAAP net loss of $3.6B in Q2 due to $4.4B AIPR&D charge from Alpine acquisition.
- Non-GAAP net loss of $3.3B; combined R&D and SG&A expenses increased to $1.3B.
- FDA accepted NDAs for vanzacaftor triple (PDUFA Jan 2, 2025) and suzetrigine (PDUFA Jan 30, 2025).
- CASGEVY launches ongoing; >35 ATCs activated; early access program in France for SCD.
- Year-end cash $10.2B vs $13.7B end of 2023; cash used for Alpine acquisition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532024000193/0000875320-24-000193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532024000193/vrtx-20240801.htm
  HTML page:      https://secwatch.observer/filing/0000875320-24-000193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer